Home » Stocks » MNKD

MannKind Corporation (MNKD)

Stock Price: $4.03 USD 0.01 (0.25%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $4.09 +0.06 (1.49%) May 13, 7:44 PM
Market Cap 1.08B
Revenue (ttm) 65.14M
Net Income (ttm) -57.24M
Shares Out 222.59M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $4.03
Previous Close $4.02
Change ($) 0.01
Change (%) 0.25%
Day's Open 3.97
Day's Range 3.91 - 4.22
Day's Volume 3,395,912
52-Week Range 1.14 - 6.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MannKind (NASDAQ:MNKD) announces its next round of earnings this Wednesday, May 12. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

2 days ago - Benzinga

WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients wi...

2 days ago - GlobeNewsWire

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

WESTLAKE VILLAGE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on April 22, 2021 it and MidCap Financial Trust, as agent, entered into an amendment of th...

2 weeks ago - GlobeNewsWire

Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® t...

3 weeks ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount o...

1 month ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...

2 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...

2 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Note...

2 months ago - GlobeNewsWire

An analyst is excited about the company's prospects.

2 months ago - The Motley Fool

WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients w...

2 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a confere...

2 months ago - GlobeNewsWire

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT ...
3 months ago - Seeking Alpha

MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Bioconnect 2021 Brokers Conference (Transcript)

4 months ago - Seeking Alpha

WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients w...

4 months ago - GlobeNewsWire

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion agr...

4 months ago - GlobeNewsWire

Kent Kresa, former Chairman, will continue to serve as a Director Kent Kresa, former Chairman, will continue to serve as a Director

5 months ago - GlobeNewsWire

Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product Lead investigational product (inhaled clofazimine) designated by the F...

5 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration ...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

6 months ago - PRNewsWire

MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Conference Call to Begin Today at 5:00 PM ET

6 months ago - GlobeNewsWire

MannKind Corporation is a biopharma company focused on developing and commercializing inhaled therapeutics for endocrinology and lung diseases. Mannkind has one FDA-approved inhalable insulin formulatio...

6 months ago - Seeking Alpha

WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to dis...

6 months ago - GlobeNewsWire

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Transcript)

7 months ago - Seeking Alpha

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)

7 months ago - Seeking Alpha

MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 22nd Annual Global Investment Conference (Transcript)

7 months ago - Seeking Alpha

MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 2second Annual Global Investment Conference (Transcript)

7 months ago - Seeking Alpha

WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patient...

8 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and ...

8 months ago - GlobeNewsWire

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients...

9 months ago - GlobeNewsWire

MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Conference Call to Begin Today at 5:00 PM ET Conference Call to Begin Today at 5:00 PM ET

9 months ago - GlobeNewsWire

WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to ...

9 months ago - GlobeNewsWire

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.

Other stocks mentioned: BCRX, FLNT, GRUB, LQDA
10 months ago - Forbes

We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intelligence (“...

Other stocks mentioned: FCEL, IDN, TTPH
10 months ago - Forbes

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)

10 months ago - Seeking Alpha

Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks. The post MannKind Is Crushing It, but Beware or You’ll Be Crus...

10 months ago - InvestorPlace

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lyt...

10 months ago - GlobeNewsWire

Momentum is still in swing from the biotech's recent presentations.

10 months ago - The Motley Fool

Investors liked the biotech's presentations at a major diabetes conference.

10 months ago - The Motley Fool

WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presente...

10 months ago - GlobeNewsWire

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyva... [Read more...]

Industry
Biotechnology
IPO Date
Jul 28, 2004
CEO
Michael Castagna
Employees
240
Stock Exchange
NASDAQ
Ticker Symbol
MNKD
Full Company Profile

Financial Performance

In 2020, MNKD's revenue was $65.14 million, an increase of 3.34% compared to the previous year's $63.04 million. Losses were -$57.24 million, 10.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 61.29% from the latest price.

Price Target
$6.50
(61.29% upside)
Analyst Consensus: Strong Buy